These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
60 related articles for article (PubMed ID: 19391309)
1. Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in CML. Larson RA Clin Adv Hematol Oncol; 2009 Feb; 7(2):S3-5. PubMed ID: 19391309 [No Abstract] [Full Text] [Related]
2. Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in GIST. Demetri GD Clin Adv Hematol Oncol; 2009 Feb; 7(2):S6-7. PubMed ID: 19391310 [No Abstract] [Full Text] [Related]
3. Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia. Mahon FX; Molimard M Leuk Res; 2009 Aug; 33(8):1147-8; author reply 1149-50. PubMed ID: 19395027 [No Abstract] [Full Text] [Related]
4. Pharmacologic monitoring and determinants of intracytoplasmic drug levels. Mahon FX Best Pract Res Clin Haematol; 2009 Sep; 22(3):381-6. PubMed ID: 19959088 [TBL] [Abstract][Full Text] [Related]
5. Longstanding remission of adult onset Still's disease under imatinib therapy in a patient with chronic myelogenous leukemia. Nagasaki Y; Miyamoto T; Henzan H; Nagafuji K; Harada M; Akashi K J Rheumatol; 2009 Jun; 36(6):1349-51. PubMed ID: 19509096 [No Abstract] [Full Text] [Related]
6. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia. Al-Kali A; Farooq S; Tfayli A J Clin Pharm Ther; 2009 Oct; 34(5):607-10. PubMed ID: 19744017 [TBL] [Abstract][Full Text] [Related]
7. Resolution of rheumatoid arthritis symptoms with imatinib mesylate. Vernon MR; Pearson L; Atallah E J Clin Rheumatol; 2009 Aug; 15(5):267. PubMed ID: 19654496 [No Abstract] [Full Text] [Related]
8. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases. Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300 [TBL] [Abstract][Full Text] [Related]
9. Dasatinib: for some difficult cases of adult leukaemia. Prescrire Int; 2008 Aug; 17(96):149-50. PubMed ID: 19496239 [No Abstract] [Full Text] [Related]
10. Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: a novel mechanism for induction of apoptosis in CML cells. Wagner MC; Dziadosz M; Melo JV; Heidel F; Fischer T; Lipka DB Leukemia; 2013 Jul; 27(7):1567-70. PubMed ID: 23232286 [No Abstract] [Full Text] [Related]
11. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia. Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476 [TBL] [Abstract][Full Text] [Related]
12. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation. Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285 [No Abstract] [Full Text] [Related]
13. Promises and pitfalls of oral cancer chemotherapy. Ergolin MJ Clin Adv Hematol Oncol; 2009 Feb; 7(2):S8-10. PubMed ID: 19391311 [No Abstract] [Full Text] [Related]
14. [Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR]. Yagasaki F; Niwa T; Abe A; Ishikawa M; Kato C; Ogura K; Sasaki H; Kyo T; Jinnai I; Bessyo M; Miyamura K Rinsho Ketsueki; 2009 Jun; 50(6):481-7. PubMed ID: 19571508 [TBL] [Abstract][Full Text] [Related]